The progression of artificial intelligence in healthcare has largely occurred in silos, with innovations developing within specific medical domains, rather than across them.
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.